CN109862787A - 氧化胆固醇硫酸酯(ocs)在治疗炎性皮肤疾病和皮肤损害中的用途 - Google Patents

氧化胆固醇硫酸酯(ocs)在治疗炎性皮肤疾病和皮肤损害中的用途 Download PDF

Info

Publication number
CN109862787A
CN109862787A CN201780048064.0A CN201780048064A CN109862787A CN 109862787 A CN109862787 A CN 109862787A CN 201780048064 A CN201780048064 A CN 201780048064A CN 109862787 A CN109862787 A CN 109862787A
Authority
CN
China
Prior art keywords
composition
ocs
skin
disease
25hc3s
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780048064.0A
Other languages
English (en)
Chinese (zh)
Inventor
任顺林
林伟琦
J·E·布朗
F·德乌维斯
M·J·金
A·R·米克斯泰尔
吴红卫
M·L·李
H·C·苏
W·塔姆拉兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Durect Corp
Original Assignee
Virginia Commonwealth University
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University, Durect Corp filed Critical Virginia Commonwealth University
Publication of CN109862787A publication Critical patent/CN109862787A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780048064.0A 2016-08-02 2017-08-01 氧化胆固醇硫酸酯(ocs)在治疗炎性皮肤疾病和皮肤损害中的用途 Pending CN109862787A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662370036P 2016-08-02 2016-08-02
US62/370,036 2016-08-02
US201762470576P 2017-03-13 2017-03-13
US62/470,576 2017-03-13
PCT/US2017/044821 WO2018026767A1 (en) 2016-08-02 2017-08-01 Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions

Publications (1)

Publication Number Publication Date
CN109862787A true CN109862787A (zh) 2019-06-07

Family

ID=61073120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780048064.0A Pending CN109862787A (zh) 2016-08-02 2017-08-01 氧化胆固醇硫酸酯(ocs)在治疗炎性皮肤疾病和皮肤损害中的用途

Country Status (12)

Country Link
US (2) US20190374554A1 (https=)
EP (1) EP3493671A4 (https=)
JP (2) JP2019524774A (https=)
KR (2) KR20230124756A (https=)
CN (1) CN109862787A (https=)
AU (2) AU2017306140A1 (https=)
BR (1) BR112019001193A2 (https=)
CA (1) CA3031211A1 (https=)
IL (1) IL264389A (https=)
MX (1) MX2019001324A (https=)
TW (2) TW202308651A (https=)
WO (1) WO2018026767A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113040140A (zh) * 2021-01-28 2021-06-29 菲吉乐科(南京)生物科技有限公司 一种适合噬菌体浸入藤本和木本植物用的辅助渗透剂及其制备方法和应用
CN113521094A (zh) * 2021-05-23 2021-10-22 广州奇维生物信息技术有限公司 一种治疗湿疹的乳剂软膏及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
HRP20220112T1 (hr) 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
WO2021163199A1 (en) * 2020-02-11 2021-08-19 Durect Corporation Treatment of infectious diseases
KR20230058444A (ko) * 2020-08-26 2023-05-03 오티카라 인코포레이티드 코, 귀 및 다른 조직 감염 및/또는 염증을 치료하기 위한 조성물, 디바이스 및 방법
CN114646702B (zh) * 2022-03-03 2023-01-06 四川大学华西医院 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
CN103476383A (zh) * 2011-04-04 2013-12-25 宝洁公司 测量转移到皮肤的皮肤剂的方法
CN104220450A (zh) * 2012-04-12 2014-12-17 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)
WO2015100312A1 (en) * 2013-12-24 2015-07-02 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (ocs)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
CN103476383A (zh) * 2011-04-04 2013-12-25 宝洁公司 测量转移到皮肤的皮肤剂的方法
CN104220450A (zh) * 2012-04-12 2014-12-17 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)
WO2015100312A1 (en) * 2013-12-24 2015-07-02 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (ocs)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113040140A (zh) * 2021-01-28 2021-06-29 菲吉乐科(南京)生物科技有限公司 一种适合噬菌体浸入藤本和木本植物用的辅助渗透剂及其制备方法和应用
CN113521094A (zh) * 2021-05-23 2021-10-22 广州奇维生物信息技术有限公司 一种治疗湿疹的乳剂软膏及其制备方法

Also Published As

Publication number Publication date
WO2018026767A1 (en) 2018-02-08
EP3493671A1 (en) 2019-06-12
JP2019524774A (ja) 2019-09-05
CA3031211A1 (en) 2018-02-08
BR112019001193A2 (pt) 2019-04-30
MX2019001324A (es) 2019-07-04
JP2022031733A (ja) 2022-02-22
AU2022205208A1 (en) 2022-08-04
KR20230124756A (ko) 2023-08-25
KR20190032530A (ko) 2019-03-27
TW201818944A (zh) 2018-06-01
AU2017306140A1 (en) 2019-02-21
TW202308651A (zh) 2023-03-01
IL264389A (en) 2019-02-28
KR102568036B1 (ko) 2023-08-17
US20210169902A1 (en) 2021-06-10
US20190374554A1 (en) 2019-12-12
EP3493671A4 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
CN109862787A (zh) 氧化胆固醇硫酸酯(ocs)在治疗炎性皮肤疾病和皮肤损害中的用途
CA3032072C (en) Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid
US20120022019A1 (en) Medicinal Steroids Cream And A Process To Make It
US20130123221A1 (en) Compositions and methods for the treatment of skin diseases
US20120136071A1 (en) Medicinal Cream For Diaper Rash And A Process To Make It
EP2303281B1 (en) Transdermal pharmaceutical compositions comprising danazol
US20120270835A1 (en) Medicinal Cream Made Using Hydrocortisone Acetate and A Process To Make The Same
WO2024125500A1 (zh) 一种局部药物组合物及其在医药上的应用
Al-Jarsha et al. A review on film forming drug delivery systems
AU2015213569B2 (en) Topical formulations of Heparin
Chakraborty et al. In vivo Study of Insulin-loaded Microemulsion Topical gel with Aloe vera for the Treatment of Dermatologic Manifestation of Diabetes
US20120108539A1 (en) Medicinal Anti Acne Cream And A Process To Make It
RU2440108C2 (ru) Фармацевтическая композиция для лечения аллергических и воспалительных заболеваний кожи
WO2019135125A1 (en) Semi-solid dosage form for topical application
WO2011027246A1 (en) A cream comprising miconazole nitrate and a biopolymer for the treatment of diaper rash
WO2010119384A2 (en) A medicinal cream made using mometasone furoate, and chitosan, and a process to make the same
Bahmani et al. Recent Innovations in Gelling Agents and Topical Gel Formulations for Psoriasis Treatment: A Patent Review
US20120035233A1 (en) Medicinal cream made using miconazole nitrate and chitosan and a process to make the same
CN120899879A (zh) 一种抗敏止痒及治疗皮肤炎性相关疾病的多肽组合制剂
CN120899927A (zh) 促进局部组织一氧化氮释放水平增加的组合物及其用途
EP2419084A2 (en) A medicinal cream made using clotrimazole and chitosan and a process to make the same
WO2010109432A1 (en) An antiscabies medicinal cream and a process to make it

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20240628

AD01 Patent right deemed abandoned